Chemotherapy for elderly patients with advanced cancer: A pilot study in Institute of Oncology Bucharest

Open access

Abstract

Objectives: First objective was better understanding of the indications of chemotherapy in elderly with advanced cancer, tolerability and toxicity of chemotherapy in this age group. The second objective was to define current practice in chemotherapy for elderly people with advanced cancer for a selected group of patients treated in Institute of Oncology Bucharest (IOB). Materials and Methods: The study makes a clinical analysis of medical records of 27 patients from the archive of Institute of Oncology Bucharest treated by the same doctor. Patients were selected according to: age ≥ 65 years, ECOG performance status 0-1, normal blood counts and blood biochemistry, histological confirmation of the diagnosis of cancer, patients should received at least 3 cycles of chemotherapy. We extract characteristics of the patients to see if they were a homogeneous group of patients and to compare them with data from the literature. Overall survival was calculated by the Kaplan Meyer curve. Results: 295 patients more then 65 years were treated in our site in 2 years 2011, 2012. 93 patients received chemotherapy and only 27 patients were enrolled in this study following inclusion criteria. Common sites of cancer were lung and breast. The most used cytostatics for lung cancer was gemcitabine and carboplatine and cyclophosphamide, metotrexat and 5 fluorouracil for breast cancer. Toxicity was mild with the prevalence of hematologic toxicity. Overall survival without taking into account the type of cancer was 27.7 month. Conclusions: For selected patients, chemotherapy was well tolerated and appears to prolong survival regardless of the location of cancer. The relatively small number of elderly patients who received chemotherapy is probably due to lack of compliance to treatment, the increased number of co-morbidities and evaluation of performance status only by the ECOG index known not to be good enough to establish the indication of chemotherapy.

1. OECD/European Union (2010), “Cancer Incidence”, in Health at a Glance: Europe 2010, OECD Publishing. http://dx.doi.org/10.1787/9789264090316-18-en.

2. Cancer Research UK. Cancer incidence by age. Available at: http:// www.cancerresearchuk.org/cancer-info/cancerstats/incidence/age/. [Last accessed on 2014 Nov 10].

3. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global Cancer Statistics. CA Cancer J Clin 2011;61:69-90.

4. Adrian Senciuc. Epidemiologia cancerelor umane. Available at: http://www.scientia.ro/biologie/37-cum-functioneaza-corpulomenesc/4050-epidemiologia-cancerelor-umane.html. [Last accessed on 2014 Nov 10].

5. Sands MB, Dantoc BP, Hartshorn A, Ryan CJ, Lujic S. Single Question in Delirium (SQiD): Testing its efficacy against psychiatrist interview, the Confusion Assessment Method and the Memorial Delirium. Palliat Med 2010;24:561-5.

6. Given B, Given CW. Older adults and cancer treatment. Cancer 2008;113(12 Suppl):3505-11.

7. Ian Olver. Chemotherapy for elderly patients with advanced cancer: is it worth it? Aust Prescr 2000;23:80-2.

8. Kumar A, Soares H, Balducci L, Djulbegovic B. Treatment tolerance and efficacy in geriatric oncology: A systematic review of phase III randomized trials conducted by five National Cancer Institutesponsored cooperative groups. J Clin Oncol 2007;25:1272-6.

9. Shenoy C1, Klem I, Crowley AL, Patel MR, Winchester MA, Owusu C, et al. Cardiovascular Complications of Breast Cancer Therapy in Older Adults. Oncologist 2011;11:1138-43.

10. Goldhirsch A, Colleoni M, Coates AS, Castiglione-Gertsch M, Gelber RD. Adding adjuvant CMF chemotherapy to either radiotherapy or tamoxifen: Are all CMFs alike? International Breast Cancer Study Group (IBCSG). Ann Oncol 1998;9:489-93.

11. Du X, Goodwin JS. Patterns of use of chemotherapy for breast cancer in older women: Findings from medicare claims data. J Clin Oncol 2001;19:1455-61.

12. Quoix E, Zalcman G, Oster JP, Westeel V, Pichon V, Lavole A, et al. Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-smallcell lung cancer: IFCT-0501 randomised, phase 3 trial. Lancet 2011;378:1079-88.

13. Gridelli C, Maione P, Comunale D, Rossi A. Adjuvant chemotherapy in elderly patients with non-small-cell lung cancer. Cancer Control 2007;14:57-62.

14. Chen YM, Perng RP, Shih JF, Tsai CM, Whang-Peng J. Chemotherapy for non-small cell lung cancer in elderly patients. Chest 2005;128:132-9.

15. Janssen-Heijnen ML, Maas HA, van de Schans SA, Coebergh JW, Groen HJ. Chemotherapy in elderly small-cell lung cancer patients: Yes we can, but should we do it?, Ann Oncol 2011;22:821-6.